Literature DB >> 9806028

Longitudinal analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte responses: a predominant gag-specific response is associated with nonprogressive infection.

O Pontesilli1, M R Klein, S R Kerkhof-Garde, N G Pakker, F de Wolf, H Schuitemaker, F Miedema.   

Abstract

To establish correlates of protective immunity during human immunodeficiency virus type 1 (HIV-1) infection, the frequencies of circulating cytotoxic T lymphocyte (CTL) precursors (p) directed against 4 HIV-1 gene products (reverse transcriptase, gag, nef, and env) were evaluated in HIV-1-infected homosexual men who progressed to AIDS and in long-term survivors over time. For both groups, HIV-1-specific CTL responses had similar kinetics and magnitude. At maximum expansion, HIV-1-specific CTLp had a median frequency of 0.2% mononuclear cells in both progressors and long-term survivors, with peaks of 0.5% and 2%, respectively. Long-term survivors maintained the established CTLp pool and presented a persistently predominant gag-specific response. The fraction and, to a lesser extent, the frequency of gag-specific CTLp were inversely correlated with virus load. In progressors, general T cell function and measurable HIV-1-specific CTLp frequencies dropped simultaneously, suggesting a further loss of virus control due to the ensuing immunodeficiency.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9806028     DOI: 10.1086/515659

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  33 in total

1.  Longitudinal phenotypic analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes: correlation with disease progression.

Authors:  G S Ogg; S Kostense; M R Klein; S Jurriaans; D Hamann; A J McMichael; F Miedema
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

2.  T cell responses to highly active antiretroviral therapy defined by chemokine receptors expression, cytokine production, T cell receptor repertoire and anti-HIV T-lymphocyte activity.

Authors:  A Giovannetti; M Pierdominici; F Mazzetta; S Salemi; M Marziali; D Kuonen; F Iebba; E A Lusi; A Cossarizza; F Aiuti
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

Review 3.  Challenges in the search for an HIV vaccine.

Authors:  Angelique A C Lemckert; Jaap Goudsmit; Dan H Barouch
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

Review 4.  Fugetaxis: active movement of leukocytes away from a chemokinetic agent.

Authors:  Fabrizio Vianello; Ivona T Olszak; Mark C Poznansky
Journal:  J Mol Med (Berl)       Date:  2005-09-03       Impact factor: 4.599

5.  Not all cytokine-producing CD8+ T cells suppress simian immunodeficiency virus replication.

Authors:  Chungwon Chung; Wonhee Lee; John T Loffredo; Benjamin Burwitz; Thomas C Friedrich; Juan Pablo Giraldo Vela; Gnankang Napoe; Eva G Rakasz; Nancy A Wilson; David B Allison; David I Watkins
Journal:  J Virol       Date:  2006-11-29       Impact factor: 5.103

6.  An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector.

Authors:  Silvia Perri; Catherine E Greer; Kent Thudium; Barbara Doe; Harold Legg; Hong Liu; Raul E Romero; Zequn Tang; Qian Bin; Thomas W Dubensky; Michael Vajdy; Gillis R Otten; John M Polo
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

Review 7.  DNA vaccines against human immunodeficiency virus type 1 in the past decade.

Authors:  Malavika Giri; Kenneth E Ugen; David B Weiner
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

8.  A consecutive priming-boosting vaccination of mice with simian immunodeficiency virus (SIV) gag/pol DNA and recombinant vaccinia virus strain DIs elicits effective anti-SIV immunity.

Authors:  Kenji Someya; Ke-Qin Xin; Kazuhiro Matsuo; Kenji Okuda; Naoki Yamamoto; Mitsuo Honda
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

9.  Continuous improvement in the immune system of HIV-infected children on prolonged antiretroviral therapy.

Authors:  Adriana Weinberg; Ruth Dickover; Paula Britto; Chengcheng Hu; Julie Patterson-Bartlett; Joyce Kraimer; Howard Gutzman; William T Shearer; Mobeen Rathore; Ross McKinney
Journal:  AIDS       Date:  2008-11-12       Impact factor: 4.177

Review 10.  Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).

Authors:  Michael Vaine; Shan Lu; Shixia Wang
Journal:  BioDrugs       Date:  2009       Impact factor: 5.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.